Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. - Wikidata - awgldk - TriplyDB

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

http://www.wikidata.org/entity/Q34505337

about

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination Vaccines in development against West Nile virus Nuclear reprogramming with a non-integrating human RNA virus.Development of replication-competent viral vectors for HIV vaccine delivery.Measles Virus Defective Interfering RNAs Are Generated Frequently and Early in the Absence of C Protein and Can Be Destabilized by Adenosine Deaminase Acting on RNA-1-Like Hypermutations.Sensitive detection of measles virus infection in the blood and tissues of humanized mouse by one-step quantitative RT-PCR Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.RNA-based viral vectors.Vaccine platform recombinant measles virus.Multivalent and Multipathogen Viral Vector Vaccines.Chikungunya Virus Vaccines: Viral Vector-Based Approaches.Development of Recombinant Measles Virus-Based Vaccines.Measles Vaccine.

P2860

Q26700080-103D2D80-5817-4E0E-9404-96F9592C72F5 Q26999702-84E84231-9D83-4447-86F9-BF96A9CE10C5 Q30645806-B9E4E6EE-88F0-46C9-A25A-B03CD6A20999 Q33694226-288DA43B-778C-43A5-8DD6-EB0262BBEE6F Q35861183-80D95417-B594-4F71-B776-C57013A8DD23 Q37226470-4B99D3DE-C2C8-4CC8-8851-1AE5575FB330 Q37520259-C26922D3-730D-4654-865A-D306C3B50CC6 Q38266413-7A2F5601-D5E7-4BDC-865E-EEC284080691 Q38657271-44E73D1E-ECAF-4669-9C8E-D9AAEC9FB49B Q38830323-8C9AF2C0-C0C6-4F2F-971E-268B347D5D00 Q39128566-E3904CD2-2E6F-45E1-BD7D-77EFF4A94F7B Q40259612-267E024B-F680-47CE-9B92-1F1C7528D61E Q46300761-A0E012BD-730B-44D2-9056-607A0D6B5E68

P2860

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

http://www.wikidata.org/entity/Q34505337

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@ast

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@en

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@nl

type

label

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@ast

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@en

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@nl

prefLabel

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@ast

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@en

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@nl

P1433

Q34505337-BFCACF01-2875-452B-88AF-53D626B7E766

P1476

Q34505337-4A3F028B-E3A8-4383-95F0-AFFFCD65DBD7

P2093

Q34505337-6633082E-C524-4649-907C-3924FDD19087

Q34505337-6FCCACA9-EB93-478D-BAA5-40CCC5E9D86F

Q34505337-712F78B3-E277-46A3-8EF9-B1055C28DE12

Q34505337-72D8676C-005A-4534-8C65-523EC5179BAB

Q34505337-921C2D0F-2D06-445C-9580-69FB518245CC

Q34505337-96497A6C-E965-4C14-8C9F-0CAB789E685B

Q34505337-96A715E4-4637-45CE-9663-EB56DCD62CD9

Q34505337-BB6C31C0-891F-4A9E-B69D-1568AB073F1A

Q34505337-C58B77D5-44D8-4B89-B7B3-071891A72970

P2860

Q34505337-04652F74-87EB-4F2F-AA8C-0EC960005301

Q34505337-04AE450E-C892-4AB6-8AED-1DF6F2EE1C86

Q34505337-07967772-0DEB-4CEC-A89F-7DF6543ABF8C

Q34505337-0B88E8D7-E286-41E3-A106-CCD018B67887

Q34505337-14CE374B-B079-4659-8462-74385F1461AC

Q34505337-28BA718D-54ED-4936-A566-52A8FD16E490

Q34505337-331EB28D-DD5B-4D22-9665-AD17463AA69C

Q34505337-332FE874-C259-43C3-AC98-18B293B437B4

Q34505337-34DE060A-A65C-4681-8204-22E3586A47BD

Q34505337-34F2D165-3003-47AE-BBF7-988D153FA966

P304

Q34505337-12CAD818-13DD-457C-830C-E7DC2E380392

P31

Q34505337-9EBE2F95-2F11-4F42-AE54-228E46DF3EAC

P356

Q34505337-9C77A53C-328D-44A2-B488-9C10DE003226

P407

Q34505337-2EA74F5B-6703-4E9A-8A0A-F26DB57614FE

P433

Q34505337-BD849053-AFBD-4240-8129-99FB3A3EB833

P478

Q34505337-3FD171D2-5ABB-42E2-B9B9-7654A1EBA4E2

P50

Q34505337-74840CB0-1B2D-495E-9994-3B31A75C029A

Q34505337-A570234F-CD66-4F07-839D-1F233A58EDB4

Q34505337-F0F665C0-91C4-4ABC-90D7-2BDE106E470F

P577

Q34505337-3B1B1155-BDCE-447E-9E99-FD6C688B17CD

P5875

Q34505337-337EE221-EAFF-4C33-852B-DE1BE53E069F

P698

Q34505337-60E081EF-A04C-405F-9827-3B91142A18F0

P921

Q34505337-ED008C49-552C-4005-A98B-C72D5001554B

P932

Q34505337-6F12CA36-DE70-4170-8314-44D172B9EB5C

P356

JOURNAL.PONE.0050397

P1433

P1476

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

@en

P2093

Bo Li

http://www.w3.org/2001/XMLSchema#string

Clarisse Lorin

http://www.w3.org/2001/XMLSchema#string

Edward Mee

http://www.w3.org/2001/XMLSchema#string

Gerald Voss

http://www.w3.org/2001/XMLSchema#string

Joanna Hall

http://www.w3.org/2001/XMLSchema#string

Marguerite Koutsoukos

http://www.w3.org/2001/XMLSchema#string

Mark Page

http://www.w3.org/2001/XMLSchema#string

Michèle Février

http://www.w3.org/2001/XMLSchema#string

Nicola Rose

http://www.w3.org/2001/XMLSchema#string

P2860

MHC heterozygosity confers a selective advantage against multiple-strain infections.

The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

CCR7 expression and memory T cell diversity in humans

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Functional diversity of helper T lymphocytes

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials

P304

e50397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0050397

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Frédéric Tangy

P577

2012-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233888885

http://www.w3.org/2001/XMLSchema#string

P698

23226275

http://www.w3.org/2001/XMLSchema#string

P921

P932

3511521

http://www.w3.org/2001/XMLSchema#string